Effects of carfilzomib alone and in combination with cisplatin on the gene expression of Bcl-2 and Bax in ovarian carcinoma cell lines

Background: Carfilzomib (CFZ), a proteasome inhibitor, has demonstrated potential in the treatment of ovarian cancer, including variants that are resistant to cisplatin (Cis).Objectives: This study aims to evaluate the effects of CFZ, both as a monotherapy and in combination with Cis, on the express...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Alireza Saedi, Javad Zavar Reza, Navid Ghasemzadeh, Moein Moradi, Behnaz Majidi, Amir Hossein Fatehi Marj, Sadegh Zarei
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Sadra Danesh Negar 2025-03-01
Saila:	Journal of Preventive and Complementary Medicine
Gaiak:	carfilzomib cisplatin ovarian cancer bcl-2 bax apoptosis
Sarrera elektronikoa:	https://www.jpcmed.com/article_216399_bd98847953a15ea8020a3ebd5742c2b6.pdf
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!